̽»¨¾«Ñ¡

I have a background in Clinical Medicine and General Surgery, with expertise as a hepatobiliary surgeon in my country. In June 2018, I joined Professor Torkel B. Brismar Group as a PhD student and successfully defended my thesis in May 2022. Currently, I am working as a postdoctoral researcher within the same group, continuing my research pursuits.

̽»¨¾«Ñ¡ Travel Grant 2023 (period 2).
Erik and Edith Fernström Foundation 2023.
Ruth and Richard Julin Foundation 2023.
Analytic Imaging Diagnostics Arena (AIDA) of Clinical Fellowship Project 2022.
̽»¨¾«Ñ¡ Travel Grant 2022 (period 2).
Medicinsk Diagnostik Karolinska Kliniknära FoU 2022.
Member of National Clinical Research School in Chronic Inflammatory Diseases (NCRSCID)(2020-2022).

During my master's studies (2014-2017), I focused on a modified ALPPS procedure (radiofrequency ablation-assisted Associating Liver Partition and Portal vein ligation for Staged hepatectomy, RALPPS) for patients with hepatitis B-related hepatocellular carcinoma. ALPPS is an innovative
technique known to stimulate accelerated liver growth in the future liver remnant, but it can also lead to increased morbidity and mortality. In this context, RALPPS was proposed as an alternative approach to classic ALPPS.

Liver function assessment plays a critical role not only in ALPPS but also in various other treatments. Accurate assessment of regional liver function
holds immense clinical significance. Therefore, my doctoral project centered on utilizing gadoxetic acid-enhanced MRI to quantitatively evaluate liver
function and predict postoperative liver failure, which is a fatal complication relating to liver function insufficiency. Additionally, I explored the integration of radiomics and machine learning techniques into liver function assessment and for the prediction of liver failure.

During my postdoctoral period, I have continued to delve into the aforementioned topics while also expanding my research field to include body composition analysis and its impact on liver growth, as well as liver cancer treatment outcomes. I have also been investigating cholangiocarcinoma and other liver cancer related areas.